Опухоли костей и система инсулиноподобных факторов роста

Иммуноферментными методами исследовали содержание ИФР-1, ИФР-2, ИФРСБ-1 и ИФРСБ-3 в сыворотке крови 113 больных новообразованиями костей. Выявлено достоверное повышение ИФР-1, -2, ИФРСБ-1, -3 при новообразованиях кости по сравнению с контролем; достоверное повышение ИФР-1, ИФР-2 по сравнению с доброкачественными новообразованиями, а также достоверное повышение уровня ИФРСБ-3 при доброкачественных новообразованиях в сравнении со злокачественными и контролем. Обнаружены различия уровней исследуемых веществ в зависимости от гистологического варианта злокачественных опухолей.

инсулиноподобные факторы роста (ИФР-1, ИФР-2), ИФР-связывающие белки (ИФРСБ-1, ИФРСБ-3), опухоли кости

1. Clemmons D.R. Value of insulin-likegrowth factor system markers in the assessment of growth hormone status. Endocrinol. Metab. Clin. North. Am. 2007, v. 36, p. 109-129.

2. Frystyk J. Free insulin-like growth factors - Measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004, v. 14, p. 337-375.

3. George Vardatsikos, Anita Sahu, Ashok K. Srivastava. The Insulin-Like Growth Factor Family: Molecular Mechanisms, Redox Regulation, and Clinical Implications, antioxidants & redoxsignaling. Volume 11, Number 5, 2009, 1165. Mary Ann Liebert, Inc.

4. Dupont J., Pierre A., Froment P., Moreau C. The insulin-like growth factor axis in cell cycle progression. Horm. Metab. Res. 2003, v. 35, p. 740-750.

5. Zhuang D., Ceacareanu A.C., Lin Y. et al. Nitric oxide attenuate sinsulin-or IGF-I-stimulated aortics mooth muscle cell motility by decree sing H2O2 levels: Essential role of cGMP. Am. J. Physiol. Heart Circ. Physiol. 2004, v. 286, p. 2103-2112.

6. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxiainducible factor1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, v. 277, p. 38205-38211.

7. Conover C.A. Insulin-like growth factor-binding proteins and bone metabolism. Am. J. Physiol. Endocrinol. Metab. 2008, v. 294, p. 10-14.

8. Ulaner G.A., Vu T.H., Li T., Hu J.F., Yao X.M., Yang Y. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum. Mol. Genet. 2003, v. 12, p. 535-549.

9. Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, v. 65, p. 11459-11468.

10. Kageyama K., Moriyama T., Hizuka N. et al. Hypoglycemica Associated with Big Insulin-Like Growth Factor II Produced during Developmen of Malignant Gibrous Hisiocytoma. End. J. 2003, v. 50, No. 6, p. 753-758.

11. Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas. J. Pathol. 2009, v. 217, p. 469-482.

12. Samani A.A., Yakar S., Le Roith D., Brodt P. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocrine Reviews. 2007, v. 28, No. 1, p. 20-47.

13. Tang Y., Zhang D., Fallavollita L., Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003, v. 63, p. 1166-1171.

14. Suem Firth, Robertc Baxter. Cellular Actions of the InsulinLike Growth Factor Binding Proteins. Endocrine Reviews. 2002, v. 23, p. 824-854.